跳至主要内容
临床试验/IRCT20180712040449N2
IRCT20180712040449N2招募中3 期

Formulation and evaluation of their efficacy of herbal capsule and decoction in patients with COVID-19 via a randomized clinical trial.

Tehran University of Medical Sciences0 个研究点目标入组 68 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
入组人数
68

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 75 years(—)
性别
All

入选标准

  • Patients with one or more of the following symptoms in addition to acute respiratory disease (ARI):• RR> 30• PO2 <93%• Pulmonary infiltration in chest x-ray• Clinical judgment of a specialist
  • Age range of 18 to 75 years in both genders
  • Lack of any serious concomitant disease of the heart, brain, or lungs, metabolic disorders, and etc.
  • The patient’s ability and own will to fill out a personal consent form for inclusion in the study
  • Patient not intubated.

排除标准

  • Pregnancy and lactation
  • Any history of allergy to any of the herbal product components
  • Inability to take a drug per-oral
  • Any condition that precludes continuance of medical intervention based on the judgment of a physician.
  • Need for intubation
  • Nausea and vomiting and oral intolerance
  • Resistant hypoxemia
  • Reduced level of consciousness
  • Hemodynamic instability
  • Hypercapnia - respiratory fatigue
  • Any manifestation of known side effects of any of the herbal product components

研究者

相似试验